Evidence map›Paper›PMID 27178165›Full record

ArticleDrug delivery and translational research2016

In vivo and in vitro sustained release of ranibizumab from a nanoporous thin-film device.

Kevin D Lance, Daniel A Bernards, Natalie A Ciaccio, Samuel D Good, Thaís S Mendes, Max Kudisch, Elliot Chan, Mynna Ishikiriyama, Robert B Bhisitkul, Tejal A Desai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery and translational research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Local controlled release of stabilized monoclonal antibodies.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kevin D LanceUC Berkeley - UCSF Graduate Group in Bioengineering, 1700 4th Street, QB3 Byers Hall, Room 203, San Francisco, CA, 94158, USA.
Daniel A BernardsDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, 94158, USA.
Natalie A CiaccioDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, 94158, USA.
Samuel D GoodDepartment of Ophthalmology, University of California San Francisco, 400 Parnassus Ave, 7th Floor, San Francisco, CA, 94143, USA.
Thaís S MendesDepartment of Ophthalmology, University of California San Francisco, 400 Parnassus Ave, 7th Floor, San Francisco, CA, 94143, USA.
Max KudischDepartment of Ophthalmology, University of California San Francisco, 400 Parnassus Ave, 7th Floor, San Francisco, CA, 94143, USA.
Elliot ChanDepartment of Ophthalmology, University of California San Francisco, 400 Parnassus Ave, 7th Floor, San Francisco, CA, 94143, USA.
Mynna IshikiriyamaDepartment of Ophthalmology, University of California San Francisco, 400 Parnassus Ave, 7th Floor, San Francisco, CA, 94143, USA.
Robert B BhisitkulDepartment of Ophthalmology, University of California San Francisco, 400 Parnassus Ave, 7th Floor, San Francisco, CA, 94143, USA.
Tejal A DesaiUC Berkeley - UCSF Graduate Group in Bioengineering, 1700 4th Street, QB3 Byers Hall, Room 203, San Francisco, CA, 94158, USA. tejal.desai@ucsf.edu.

Funding

UCSF/UCB Joint Graduate Group in BIoengineeringT32GM008155 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DESAI, TEJAL A. · 1985 to 2020
$12.2M
Nanoporous Films for Ocular Drug DeliveryR01EY021574 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DESAI, TEJAL A. · 2011 to 2014
$1.5M
NEI NIH HHS R01 EY021574NIGMS NIH HHS T32 GM008155
6 · The paper itself

Abstract

Current administration of ranibizumab and other therapeutic macromolecules to the vitreous and retina carries ocular risks, a high patient treatment burden, and compliance barriers that can lead to suboptimal treatment. Here we introduce a device that produces sustained release of ranibizumab in the vitreous cavity over the course of several months. Composed of twin nanoporous polymer thin films surrounding a ranibizumab reservoir, these devices provide release of ranibizumab over 16 weeks in vitro and 12 weeks in vivo, without exhausting the initial drug payload. Following implantation in vivo, devices were well-tolerated and showed no sign of immune response. This platform presents a potential solution to the challenge of delivering protein therapeutics to the vitreous and retina for sustained periods of time.

Indexed as

Drug Delivery SystemsAngiogenesis InhibitorsAnimalsDelayed-Action PreparationsDrug LiberationFemaleFluorescein-5-isothiocyanateMicroscopy, Electron, ScanningNanoporesPolyestersRabbitsRanibizumabVitreous BodyAngiogenesis InhibitorsDelayed-Action PreparationsFluorescein-5-isothiocyanatepolycaprolactonePolyestersRanibizumabBiodegradableControlled releaseDrug deliveryNanoporousRanibizumabSustained release

Identifiers

PMID27178165
PMCPMC5097678

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.